Evidence map›Paper›PMID 39766027›Full record

ReviewCancers2024

Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies.

Adam Khorasanchi, Karan Jatwani, Lingbin Meng, Katharine A Collier, Debasish Sundi, Shawn Dason, Eric A Singer, Dharmesh Gopalakrishnan, Amir Mortazavi, Gurkamal Chatta and 1 more

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Adam KhorasanchiDivision of Hospital Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.ORCID 0000-0002-4603-376X
Karan JatwaniDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Lingbin MengDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Katharine A CollierDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.ORCID 0000-0003-0485-8031
Debasish SundiDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.ORCID 0000-0001-6980-4777
Shawn DasonDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Eric A SingerDivision of Urologic Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Dharmesh GopalakrishnanDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Amir MortazaviDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.
Gurkamal ChattaDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Yuanquan YangDivision of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA.ORCID 0000-0002-5209-9247

Funding

Paul Calabresis Career Development Award For Clinical Oncology K12CA132783 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI PEREZ-SOLER, ROMAN, VERMA, AMIT K. · 2009 to 2019
$8.2M
Characterizing the immune infiltrate in muscle-invasive urothelial carcinomaK08CA277016 · NCI · OHIO STATE UNIVERSITY · PI Katharine A. Collier · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA277016NCI NIH HHS K12 CA132783
6 · The paper itself

Abstract

Genitourinary (GU) malignancies are common and associated with significant morbidity and mortality. In patients with localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite definitive treatment, many patients with high-risk localized disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes the current evidence for neoadjuvant immunotherapy in patients with localized high-risk GU cancers including renal cell carcinoma, urothelial carcinoma, prostate cancer, penile squamous cell carcinoma, and testicular germ cell tumors. We also discuss ongoing clinical trials and candidate biomarkers to optimize patient selection and improve treatment outcomes.

Indexed as

immune checkpoint inhibitorsimmunotherapyneoadjuvantpenile squamous cell carcinomaprostate cancerrenal cell carcinomatesticular germ cell tumorsurothelial carcinoma

Identifiers

PMID39766027
PMCPMC11674059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.